Your browser doesn't support javascript.
loading
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Rodriguez-Meira, Alba; Norfo, Ruggiero; Wen, Sean; Chédeville, Agathe L; Rahman, Haseeb; O'Sullivan, Jennifer; Wang, Guanlin; Louka, Eleni; Kretzschmar, Warren W; Paterson, Aimee; Brierley, Charlotte; Martin, Jean-Edouard; Demeule, Caroline; Bashton, Matthew; Sousos, Nikolaos; Moralli, Daniela; Subha Meem, Lamia; Carrelha, Joana; Wu, Bishan; Hamblin, Angela; Guermouche, Helene; Pasquier, Florence; Marzac, Christophe; Girodon, François; Vainchenker, William; Drummond, Mark; Harrison, Claire; Chapman, J Ross; Plo, Isabelle; Jacobsen, Sten Eirik W; Psaila, Bethan; Thongjuea, Supat; Antony-Debré, Iléana; Mead, Adam J.
Affiliation
  • Rodriguez-Meira A; Haematopoietic Stem Cell Biology Laboratory, Medical Research Council Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. albarmeira@gmail.com.
  • Norfo R; NIHR Biomedical Research Centre, University of Oxford, Oxford, UK. albarmeira@gmail.com.
  • Wen S; Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA. albarmeira@gmail.com.
  • Chédeville AL; Broad Institute, Cambridge, MA, USA. albarmeira@gmail.com.
  • Rahman H; Haematopoietic Stem Cell Biology Laboratory, Medical Research Council Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • O'Sullivan J; NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Wang G; Centre for Regenerative Medicine 'Stefano Ferrari', Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Louka E; Haematopoietic Stem Cell Biology Laboratory, Medical Research Council Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Kretzschmar WW; NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Paterson A; Medical Research Council Centre for Computational Biology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Brierley C; INSERM, UMR 1287, Villejuif, France.
  • Martin JE; Gustave Roussy, Villejuif, France.
  • Demeule C; Université Paris Saclay, Gif-sur-Yvette, France.
  • Bashton M; Université Paris Cité, Paris, France.
  • Sousos N; Haematopoietic Stem Cell Biology Laboratory, Medical Research Council Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Moralli D; NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Subha Meem L; Haematopoietic Stem Cell Biology Laboratory, Medical Research Council Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Carrelha J; NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Wu B; Haematopoietic Stem Cell Biology Laboratory, Medical Research Council Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Hamblin A; NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Guermouche H; Medical Research Council Centre for Computational Biology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Pasquier F; Haematopoietic Stem Cell Biology Laboratory, Medical Research Council Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Marzac C; NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Girodon F; Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
  • Vainchenker W; Karolinska University Hospital, Stockholm, Sweden.
  • Drummond M; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Harrison C; Haematopoietic Stem Cell Biology Laboratory, Medical Research Council Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Chapman JR; NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Plo I; Haematopoietic Stem Cell Biology Laboratory, Medical Research Council Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Jacobsen SEW; NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Psaila B; Center for Hematological Malignancies, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
  • Thongjuea S; INSERM, UMR 1287, Villejuif, France.
  • Antony-Debré I; Gustave Roussy, Villejuif, France.
  • Mead AJ; Université Paris Saclay, Gif-sur-Yvette, France.
Nat Genet ; 55(9): 1531-1541, 2023 09.
Article in En | MEDLINE | ID: mdl-37666991
ABSTRACT
Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 'multihit' HSPC clones at transformation, with a leukemia stem cell transcriptional signature strongly predictive of adverse outcomes in independent cohorts, across both TP53-mutant and wild-type (WT) AML. Through analysis of serial samples, antecedent TP53-heterozygous clones and in vivo perturbations, we demonstrate a hitherto unrecognized effect of chronic inflammation, which suppressed TP53 WT HSPCs while enhancing the fitness advantage of TP53-mutant cells and promoted genetic evolution. Our findings will facilitate the development of risk-stratification, early detection and treatment strategies for TP53-mutant leukemia, and are of broad relevance to other cancer types.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia / Multiomics Type of study: Prognostic_studies / Screening_studies Limits: Humans Language: En Journal: Nat Genet Journal subject: GENETICA MEDICA Year: 2023 Type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia / Multiomics Type of study: Prognostic_studies / Screening_studies Limits: Humans Language: En Journal: Nat Genet Journal subject: GENETICA MEDICA Year: 2023 Type: Article Affiliation country: United kingdom